Neutrophil-to-lymphocyte ratio may be associated with the outcome in patients with prostate cancer

SpringerPlus

Volumn 4, Issue 1, 2015, Pages

  Minardi, Daniele ^a   Scartozzi, M ^a   Montesi, L ^a   Santoni, M ^a   Burattini, L ^a   Bianconi, M ^a   Lacetera, V ^a   Milanese, G ^a   Cascinu, S ^a   Muzzonigro, G ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Neutrophil to lymphocyte ratio; Progression free survival; Prostate cancer

Indexed keywords

EID: 84931271396     PISSN: None     EISSN: 21931801     Source Type: Journal    
DOI: 10.1186/s40064-015-1036-1     Document Type: Article

References (21)

1. An X, Ding PR, Li YH, Wang FH, Shi YX, Wang ZQ et al (2010) Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer. Biomarkers 15:516–522
2. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860–867
3. Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds) (2010) American joint committee on cancer staging manual, 7th edn. Springer, New York
4. Feng JF, Huang Y, Liu JS (2013) Combination of neutrophil lymphocyte ratio and platelet lymphocyte ration is a useful predictor of postoperative survival in patients with esophageal squamous cell carcinoma. Onco Targets Therapy 6:1605–1612
5. Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation and cancer. Cell 140:833–899
6. Gueron G, De Servi A, Vazquez E (2012) Advanced prostate cancer: reinforcing the strings between inflammation and the metastatic behavior. Prostate Cancer Prostatic Dis 15:335–343
7. Keizman D, Ish-Shalom M, Huang P, Eisenberg MA, Pili R, Hammers H et al (2012) The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival, and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma. Eur J Cancer 48(2):202–208
8. Li MX, Liu XM, Zhang XF, Zhang JF, Wang WL, Zhu Y et al (2014) Prognostic role of neutrophil-to-lymphocyte ratio in colorectal cancer: a systematic review. Int J Cancer 134:2403–2413
9. McMillan DC (2009) Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care 12:223–226
10. Moul JW (2000) Prostate specific antigen only progression of prostate cancer. J Urol 163(6):1632–1642
11. Négrier S, Escudier B, Gomez F, Douillard J-Y, Ravaud A, Chevreau C et al (2002) Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinoma treated by cytokines: a report from the Group Français d’Immunothérapie. Ann Oncol 13:1460–1468
12. Ohno Y, Nakashima J, Ohori M, Hatano T, Tachibana M (2010) Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of recurrence in patients with nonmetastatic renal cell carcinoma. J Urol 184:873–878
13. Olson BM, Johnson LE, McNeel DG (2013) The androgen receptor: a biologically relevant vaccine target for the treatment of prostate cancer. Cancer Immunol Immunother 62(3):585–596
14. Pinato DJ, Stebbing J, Ishizuka M, Khan SA, Wasan HS, North BV et al (2012) A novel and validated prognostic index in hepatocellular carcinoma: the inflammation based index (IBI). J Hepatol 57:1013–1020
15. Pinato DJ, Stavraka C, Flynn MJ, Forster MD, O’Cathail SM, Seckl MJ et al (2014) An inflammation-based score can optimize the selection of patients with advanced cancer considered for early phase clinical trial. Plos One 9(1):1–10(e83279)
16. Proctor MJ, Morrison DS, Talwar D, Balmer SM, Fletcher CD, O’Reilly DS et al (2011) A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow inflammation Outcome Study. Eur J Cancer 47(17):2633–2641
17. Rossi L, Santoni M, Crabb SJ, Scarpi E, Burattini L, Chau C et al (2015) High neutrophil-to-lymphocyte ratio persistent during first-line chemotherapy predicts poor clinical outcome in patients with advanced urothelial cancer. Ann Surg Oncol 22:1377–1384
18. Schmidt H, Bastholt L, Geertsen P, Douillard JY, Ravaud A, Chevreau C et al (2005) Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model. Br J Cancer 93:273–278
19. Teramukai S, Kitano T, Kishida Y, Kawahara M, Kubota K, Komuta K et al (2009) Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: an analysis of Japan Multinational Trial Organization LC00-03. Eur J Cancer 45:1950–1958
20. Wei Y, Jiang YZ, Qian WH (2014) Prognostic role of NLR in urinary cancers: a meta-analysis. Plos One 9(3):1–6(e92079)
21. Zahorec R (2001) Ratio of neutrophil to lymphocyte count—rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy 102:5–14